Hyderabad’s ambition to consolidate its position as India’s life sciences capital received fresh momentum after the Union Budget 2026-27 unveiled the Biopharma SHAKTI programme, a ₹10,000 crore push to strengthen domestic production of biologics and biosimilars. Telangana officials say the state’s new policy framework is aligned to leverage the Biopharma SHAKTI initiative, potentially deepening the city’s role in advanced pharmaceutical manufacturing.
Hyderabad already hosts more than 2,000 life sciences enterprises and accounts for a significant share of national pharmaceutical output. The Biopharma SHAKTI scheme, announced by the Union Finance Ministry, is designed to scale up indigenous capabilities in complex biological medicines used to treat chronic conditions such as diabetes and cancer. Industry analysts believe the programme could accelerate investments in research parks, biomanufacturing units and specialised logistics infrastructure.The state government recently unveiled its Next Gen Life Sciences Policy 2026-2030 at the World Economic Forum in Davos, outlining incentives for high-value segments including cell and gene therapies, vaccines and biosimilars. Officials familiar with the framework say the policy emphasises research partnerships, skill development and cluster-based expansion.
Global majors such as Amgen, Eli Lilly and Sanofi already operate in Hyderabad, alongside domestic firms. Their presence has helped shape a dense ecosystem spanning bulk drug parks, formulation units and clinical research facilities. With Biopharma SHAKTI funding, the focus is expected to shift further towards high-end biologics manufacturing, which demands sophisticated cleanroom facilities, cold chain logistics and regulatory compliance systems.Urban economists note that the expansion of life sciences clusters has direct implications for land use, water management and energy consumption. Biopharmaceutical production is resource-intensive, requiring uninterrupted power and treated water. As Hyderabad grows, balancing industrial expansion with zero-carbon targets and water sustainability will be critical.
Real estate consultants are also tracking increased demand for laboratory-ready commercial spaces and integrated research campuses. Such facilities often anchor surrounding residential and social infrastructure, shaping new micro-markets within metropolitan regions. Transport connectivity — including metro links and arterial highways — plays a decisive role in attracting global talent and investment.Public health experts argue that strengthening domestic biologics production could reduce import dependency and improve affordability of advanced therapies. This aligns with broader national goals of addressing the rising burden of non-communicable diseases.
However, specialists caution that sustained success under the Biopharma SHAKTI programme will depend on regulatory agility, intellectual property clarity and environmental compliance. Waste disposal and effluent treatment in pharmaceutical clusters remain areas requiring strict oversight.For Hyderabad, the convergence of central funding and state policy offers a strategic window. If infrastructure expansion is planned responsibly and environmental safeguards are enforced, the city’s life sciences ecosystem could evolve into a globally competitive, climate-conscious industrial hub — reinforcing its dual identity as a technology and healthcare powerhouse.
Also Read:Chennai Weather Shifts As Rain System Forms
Hyderabad Biopharma SHAKTI Fuels Life Sciences
